Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pilot study of mutant ras peptide-based vaccine as an adjuvant treatment in pancreatic and colorectal cancers.

Cancer immunology, immunotherapy : CII - 1 Sept 2008

Toubaji Antoun, Achtar Moujahed, Provenzano Maurizio, Herrin Vincent E, Behrens Robert, Hamilton Michael, Bernstein Sarah, Venzon David, Gause Barry, Marincola Francesco, Khleif Samir N

Abstract excerpt

INTRODUCTION: There is mounting evidence describing the immunosuppressive role of bulky metastatic disease, thus countering the therapeutic effects of tumor vaccine. Therefore, adjuvant immunotherapy may have a better impact on clinical outcome. In this phase II clinical trial, we aimed to test the feasibility of using a specific mutant ras peptide vaccine as an adjuvant immunotherapy in pancreatic and colorectal...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adjuvants, Immunologic
Share to Cancer Vaccines

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Colorectal Neoplasms

Share to Disease-Free Survival

Share to Genes, ras

Share to Immunotherapy

Share to Pancreatic Neoplasms

Share to Pilot Projects

Source

Open in PubMed Open full text

Identifiers

PMID: 18297281
DOI: 10.1007/s00262-008-0477-6
PMCID: PMC11030622

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pilot study of mutant ras peptide-based vaccine as an adjuvant treatment in pancreatic and colorectal cancers.PMID 18297281Read ↗

Targeting mutated K-ras in pancreatic adenocarcinoma using an adjuvant vaccine.Semantic proximity Read ↗

Trials of vaccines for pancreatic ductal adenocarcinoma: Is there any hope of an improved prognosis?Semantic proximity Read ↗

Vaccination with mutant ras peptides and induction of T-cell responsiveness in pancreatic carcinoma patients carrying the corresponding RAS mutation.Semantic proximity Read ↗

Strategies for developing and optimizing cancer vaccinesSemantic proximity Read ↗

A Peptide-Based Neoantigen Vaccine for Patients With Advanced Pancreatic Cancer Refractory to Standard TreatmentSemantic proximity Read ↗

Mutant KRAS vaccine with dual checkpoint blockade in resected pancreatic cancer: a phase I trial.Semantic proximity Read ↗

Vaccines in oncology: background and clinical potential.Semantic proximity Read ↗

A phase I vaccine trial with peptides reflecting ras oncogene mutations of solid tumors.Semantic proximity Read ↗

The antitumor and immunoadjuvant effects of IFN-alpha in combination with recombinant poxvirus vaccines.Semantic proximity Read ↗

Long-peptide vaccination with driver gene mutations in p53 and Kras induces cancer mutation-specific effector as well as regulatory T cell responsesSemantic proximity Read ↗

In situ vaccination using unique TLR9 ligand K3-SPG induces long-lasting systemic immune response and synergizes with systemic and local immunotherapySemantic proximity Read ↗

An open-label, prospective phase I/II study evaluating the immunogenicity and safety of a ras peptide vaccine plus GM-CSF in patients with non-small cell lung cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.